Biotech Values

[iOwnSomeBio]

Arixtra bests Lovenox a moot point.

From another board
http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=1608636393&tid=mnta&sid=....

It was a clear win but only because the study was biased.

Lovenox patients were given a dose of heparin (100 units), arixtra patients weren't. That would make the bleeding outcomes impossible to compare since heparin contributes to bleeding. So the study was flawed.

This study was out many months ago and as far as I know arixtra hasn't picked up any sales. As far as investing in mnta, arixtra is a pretty trivial point right now. mnta needs to get m-lovenox approved otherwise it's all moot.